Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Key Points

• Amneal experienced a significant rise in short interest, up 18.9% to 8,556,479 shares as of April 15, implying a 6.1 days-to-cover ratio and about 3.3% of shares sold short.
• Quarterly results beat estimates—EPS $0.26 versus $0.15 expected and revenue $723M versus $709.8M—and the company set FY2026 guidance of $0.95–1.05 EPS (Q1 2026 EPS guidance $0.27).
• Analyst sentiment is a "Moderate Buy" with six Buy and two Hold ratings and a $15 consensus target, though views vary (UBS $19 target; Zacks lowered to Hold).

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totaling 8,556,479 shares, an increase of 18.9% from the March 31st total of 7,193,959 shares. Based on an average trading volume of 1,392,898 shares, the days-to-cover ratio is presently 6.1 days. Currently, 3.3% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Zacks Research lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 6th. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a "buy" rating and a $19.00 price target on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

Amneal Pharmaceuticals Stock Up 0.5%

AMRX stock opened at $12.80 on Thursday. Amneal Pharmaceuticals has a 12 month low of $7.02 and a 12 month high of $15.42. The firm has a market cap of $4.03 billion, a P/E ratio of 33.69 and a beta of 1.32. The company's 50-day moving average price is $12.91 and its two-hundred day moving average price is $12.61.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 4.53% and a negative return on equity of 276.67%. The firm had revenue of $723.00 million for the quarter, compared to analyst estimates of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. Equities analysts predict that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. New York State Teachers Retirement System bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $376,000. Y Intercept Hong Kong Ltd bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $136,000. Strs Ohio increased its holdings in Amneal Pharmaceuticals by 158.5% in the 1st quarter. Strs Ohio now owns 10,600 shares of the company's stock valued at $132,000 after buying an additional 6,500 shares during the period. MQS Management LLC bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $325,000. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at approximately $936,000. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.